SMMT
NASDAQSummit Therapeutics Inc.
News · 26 weeks43-22%
2026-03-012026-08-23
Mix3190d
- SEC Filings11(35%)
- Other9(29%)
- Insider5(16%)
- Earnings3(10%)
- Analyst2(6%)
- Offering1(3%)
Latest news
25 items- PRIvonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in ChinaHARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS Superiority vs. Anti-PD-(L)1 Plus Chemotherapy First Phase III Ivonescimab Readout beyond NSCLC Demonstrates Significant OS Benefit Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). HARMONi-GI1 is a single-region, multi-center, Phase III study conducted in China and sponsored by Akeso, with all relev
- ANALYSTSummit Therapeutics upgraded by Bernstein with a new price targetBernstein upgraded Summit Therapeutics from Underperform to Mkt Perform and set a new price target of $11.90
- PRIvonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet OncologyFirst Immunotherapy-Based Regimen to Show Statistically Significant and Clinically Meaningful PFS Benefit in a Global Phase III Study of EGFR-Mutated NSCLC after Third-Generation EGFR TKI Progression Updated OS Data to Be Presented at WCLC 2026 Summit Therapeutics Inc. (NASDAQ:SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. In HARMONi, ivonescimab in combination with platinum-doublet chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to placebo plus platinum-doublet chemotherapy in patients with epidermal growth f
- PRIvonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung CancerMarks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Statistically Significant Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in NSCLC or Any Tumor Type Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-i
- ANALYSTSummit Therapeutics upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Summit Therapeutics from Underperform to Market Perform and set a new price target of $13.00
- SECSummit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Summit Therapeutics Inc. (0001599298) (Filer)
- PRSummit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder CancerHARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Cancer, Adding to Global Phase III Ivonescimab Studies in NSCLC and CRC Clinical Trial Site Activations Globally Planned to Begin by Q4 2026 Summit Therapeutics Inc. (NASDAQ:SMMT) today announced the expansion of its global registration-enabling clinical development program for the novel, potential first-in-class investigational bispecific antibody ivonescimab, into urothelial carcinoma, or bladder cancer, with the initiation of the global, multi-regional Phase II/III HARMONi-GU1 trial. Summit is starting a randomized Phase II/III clinical study, HARMONi-GU1, to evaluate ivonescimab plus t
- SECSEC Form 8-K filed by Summit Therapeutics Inc.8-K - Summit Therapeutics Inc. (0001599298) (Filer)
- SECSEC Form 424B5 filed by Summit Therapeutics Inc.424B5 - Summit Therapeutics Inc. (0001599298) (Filer)
- SECSEC Form 10-Q filed by Summit Therapeutics Inc.10-Q - Summit Therapeutics Inc. (0001599298) (Filer)
- SECSummit Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Summit Therapeutics Inc. (0001599298) (Filer)
- PRSummit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy Ivonescimab Plus Chemotherapy Achieves Statistically Significant and Clinically Meaningful Overall Survival Benefit in 1L Squamous NSCLC HARMONi-6 Trial Conducted in China, the First Phase III Head-to-Head Clinical Study to Demonstrate Superiority over an Anti-PD-(L)1 Antibody-Containing Regimen HARMONi-3 Global Phase III 1L NSCLC Study: Squamous Cohort Final PFS Analysis Events Expected to Be Reached in Second Half of 2026 with Interim OS Analyses Planned; Non-Squamous Cohort PFS Events Expect
- SECSummit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Summit Therapeutics Inc. (0001599298) (Filer)
- PRIvonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi StudyWestern Patients Achieved OS HR of 0.76, Consistent with Asian Patients in this Global Phase III Study Summit Therapeutics Inc. (NASDAQ:SMMT) today announced results of an updated overall survival (OS) analysis from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. Ivonescimab plus platinum-doublet chemotherapy in this trial continues to show a positive OS trend and a consistent efficacy and safety profile in Asian and western patients when compared to chemotherapy alone. The HARMONi study is evaluating ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with endot
- PRSummit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026Conference Call to Be Held at 4:30 p.m. EDT Summit Therapeutics Inc. (NASDAQ:SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progress on Thursday, July 23, 2026. The call is scheduled to take place at 4:30 p.m. EDT. The live and archived webcast can be accessed through the Investor Information section of the company’s website, www.smmttx.com. About Summit Therapeutics Inc. Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of lif
- PRSummit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.Summit Therapeutics Inc. (NASDAQ:SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artificial intelligence (AI)-native biopharma company focused on advancing late-stage programs in life-threatening indications with urgent unmet medical needs. Previously, ridinilazole was evaluated in Summit’s Phase III Ri-CoDIFy study for the treatment of patients suffering from C. difficile infection (C. diff. infection or CDI), an area of high unmet need. The study showed that ridinilazole resulted in a higher observed Sustained Clinical Response (SCR) rate than
- PRThe New War on Cancer: Four Public Companies Helping Lead a Medical RevolutionDENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on surgery, radiation, and chemotherapy. While those therapies have saved countless lives, a new generation of biotechnology companies is working to make cancer treatment smarter, more targeted, and potentially more effective. Rather than simply attacking rapidly dividing cells, researchers are developing therapies designed to identify specific genetic mutations, harness the immune system, and deliver treatments directly to cancer cells while minimizing damage to healthy tissue. Seve
- SECSummit Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Summit Therapeutics Inc. (0001599298) (Filer)
- INSIDERCo-Chief Executive Officer Zanganeh Mahkam bought $49,987,200 worth of shares (3,810,000 units at $13.12) (SEC Form 4)4 - Summit Therapeutics Inc. (0001599298) (Issuer)
- INSIDERCo-Chief Executive Officer Duggan Robert W bought $49,987,200 worth of shares (3,810,000 units at $13.12), increasing direct ownership by 0.67% to 573,883,879 units (SEC Form 4)4 - Summit Therapeutics Inc. (0001599298) (Issuer)
- SECSummit Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Summit Therapeutics Inc. (0001599298) (Filer)
- PRSummit Therapeutics Announces Proposed Public Offering of Common StockSummit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Summit. In addition, Summit intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Summit inten
- SECSEC Form S-3ASR filed by Summit Therapeutics Inc.S-3ASR - Summit Therapeutics Inc. (0001599298) (Filer)
- INSIDERCo-Chief Executive Officer Duggan Robert W bought $1,460,000 worth of shares (100,000 units at $14.60) (SEC Form 4)4 - Summit Therapeutics Inc. (0001599298) (Issuer)
- INSIDERCo-Chief Executive Officer Zanganeh Mahkam bought $1,460,000 worth of shares (100,000 units at $14.60) (SEC Form 4)4 - Summit Therapeutics Inc. (0001599298) (Issuer)
SMMT FAQ
7 questionsWhat does Summit Therapeutics Inc. do?
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat...Where does SMMT stock trade?
Summit Therapeutics Inc. (SMMT) is listed on NASDAQ.What sector and industry is SMMT in?
Summit Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Summit Therapeutics Inc. go public?
Summit Therapeutics Inc. (SMMT) completed its IPO in 2015.What are analysts saying about SMMT?
Summit Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Mkt Perform with a $1190.00 price target on 2026-08-25. Recent price targets range from $1190.00 to $4500.00.What companies are similar to SMMT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SMMT side-by-side with any of them on Quantisnow.How can I track SMMT on Quantisnow?
Quantisnow aggregates Summit Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SMMT to receive live email and push alerts on every new disclosure.